Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2016

View Archived Issues

Antares Pharma reports safety results from phase III trial of Quickshot testosterone

Vical starts phase II trial of VCL-HB01 in HSV-2 infection

FDA grants fast track designation to Axovant's intepirdine

Biogen completes rolling submission of NDA for nusinersen to FDA

Summit Therapeutics gains FDA fast track status for ezutromid

Versartis starts phase III trial of somavaratan in children with GHD

Abbvie submits sNDA to the FDA for ibrutinib

Cerecor acquires exclusive rights from Eli Lilly for CERC-611

FDA issues complete response letter for Remoxy extended-release capsules

HSP90 inhibitor/SN-38 drug conjugate STA-8666 effective in pediatric sarcoma models

Phase III COLUMBUS trial of encorafenib plus binimetinib meets primary endpoint

Novartis patents angiotensin AT2 receptor antagonists

Emory University discloses RNA-directed RNA polymerase inhibitors

Merck & Co. describes IRAK-4 inhibitors

BioMarin Pharmaceutical develops CGS inhibitors

LTT Bio-Pharma presents muscarinic M3 receptor antagonists

FDA grants emergency use authorization for Vela Diagnostics' Zika virus molecular assay

Alpha4betadelta GABARs exert anticonvulsant effects during puberty

Circulating C19MC microRNAs as biomarkers of infantile hemangioma

Idera Pharmaceuticals reports initial data from phase I/II trial of IMO-2125

Novel GLP-1/FGF21 dual agonist in preclinical studies

Pfizer not to split into two separate companies

Sciclone Pharmaceuticals reports advancements in several trials for thymalfasin and PT-112

New start-up Ilkos Therapeutics gets launched for the development of S-42909

Novel hybrid peptides as a promising strategy for type 2 diabetes

FDA places phase III Multikine trial on clinical hold

ARNT2 shows promise as a therapeutic target in MS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...